Inositols in the Treatment of Insulin-Mediated Diseases

G. Muscogiuri, Stefano Palomba, Antonio Simone Laganà, Francesco Orio

Research output: Contribution to journalReview articlepeer-review


A growing body of research is currently focused on the role of inositol isomers and in particular myo-inositol (MYO-INS) and D-chiroinositol (DCI) in the treatment of insulin resistance states. Both isomers have been shown to exert insulin-mimetic action and to lower postprandial glucose. Further, insulin resistance-related diseases were associated to derangements in inositol metabolism. Thus, the aim of this review is to provide current evidence on the potential benefits of inositol isomers (MYO-INS and DCI) in the treatment of disease associated to insulin resistance such as polycystic ovary syndrome (PCOS), gestational diabetes, and metabolic syndrome. Finally, molecular insights into inositol insulin-sensitizing effects will be covered focusing on the possible role of inositol glycans as insulin second messengers.

Original languageEnglish
Article number3058393
JournalInternational Journal of Endocrinology
Publication statusPublished - 2016

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems


Dive into the research topics of 'Inositols in the Treatment of Insulin-Mediated Diseases'. Together they form a unique fingerprint.

Cite this